ARTICLE | Emerging Company Profile
Blackfynn: optimizing trial design for neurodegenerative therapies
Emerging Company Profile: Blackfynn aims to bring deprioritized late-stage neurodegenerative disease programs to market
March 20, 2021 1:38 AM UTC
Blackfynn has pivoted from a data service company to a drug developer that in-licenses clinical assets for neurodegenerative disease, starting with a Phase III-ready program for Parkinson’s.
Blackfynn Inc. uses its platform to integrate existing clinical data on candidates that have failed or been deprioritized due to limitations in trial design, and uses that data to identify the optimal patient populations, dosing and endpoints for future trials. ...